{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T11:22:04Z","timestamp":1698924124277},"reference-count":50,"publisher":"Akademiai Kiado Zrt.","issue":"20","license":[{"start":{"date-parts":[[2021,5,16]],"date-time":"2021-05-16T00:00:00Z","timestamp":1621123200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2021,5,16]]},"abstract":"<jats:p><jats:bold>\u00d6sszefoglal\u00f3.<\/jats:bold> C\u00e9lunk, hogy k\u00f6zlem\u00e9ny\u00fcnkben \u00f6sszefoglaljuk a\n                    pachychorioidealis k\u00f3rk\u00e9pekkel kapcsolatos ismereteket egy-egy saj\u00e1t esettel\n                    illusztr\u00e1lva. Az irodalmi adatok \u00e9s a saj\u00e1t klinikai tapasztalatok alapj\u00e1n\n                    \u00f6sszegezt\u00fck a pachychorioidealis k\u00f3rk\u00e9pekkel kapcsolatos ismereteinket, az\n                    alcsoportok kezel\u00e9si lehet\u0151s\u00e9geir\u0151l \u00f6sszefoglal\u00f3 folyamat\u00e1br\u00e1t k\u00e9sz\u00edtett\u00fcnk. A\n                    pachychorioidealis k\u00f3rk\u00e9pekbe a k\u00f6vetkez\u0151 betegs\u00e9gek tartoznak: centr\u00e1lis\n                    serosus chorioretinopathia (CSCR), pachychorioidealis pigmentepitheliopathia\n                    (PPE), pachychorioidealis neovasculopathia (PNV), polypoid chorioidealis\n                    vasculopathia (PCV), peripapillaris pachychorioidealis syndroma (PPS), focalis\n                    chorioideaexcavatio (FCE). A pachychorioidealis k\u00f3rk\u00e9pek k\u00f6z\u00f6s jellemz\u0151je a\n                    chorioidea kvantitat\u00edv vagy kvalitat\u00edv elt\u00e9r\u00e9sei, melyekhez gyakran subretinalis\n                    folyad\u00e9kgy\u00fclem t\u00e1rsul. A betegs\u00e9gcsoportnak jelenleg nincs standard kezel\u00e9si\n                    protokollja; a t\u00f6bbf\u00e9le kezel\u00e9si m\u00f3d k\u00f6z\u00fcl n\u00e9h\u00e1ny hat\u00e9konyabbnak bizonyul, az\n                    alcsoportok k\u00f6z\u00f6tt azonban l\u00e9nyeges k\u00fcl\u00f6nbs\u00e9gek mutatkoznak. \u00d6sszegezz\u00fck, hogy\n                    melyik alcsoportban \u00e9rdemes eplerenonetablett\u00e1s kezel\u00e9ssel,\n                    mikropulzusl\u00e9zer-kezel\u00e9ssel, verteporfinos fotodin\u00e1mi\u00e1s kezel\u00e9ssel (PDT) vagy\n                    intravitrealis anti-VEGF-injekci\u00f3s kezel\u00e9ssel kezdeni. Orv Hetil. 2020; 162(20):\n                    770\u2013781.<\/jats:p>\n                <jats:p><jats:bold>Summary.<\/jats:bold> The aim of this study is to present our knowledge about\n                    pachychoroid diseases using case reports, literature review and our own clinical\n                    experiences. A summary flow chart of treatment options for the subgroups was\n                    prepared, too. Pachychoroid diseases include the following: central serous\n                    chorioretinopathy (CSCR), pachychoroid pigment epitheliopathy (PPE),\n                    pachychoroid neovasculopathy (PNV), polypoidal choroidal vasculopathy (PCV),\n                    peripapillary pachychoroid syndrome (PPS), focal choroidal excavation (FCE). A\n                    common feature of pachychoroid diseases is the quantitative or qualitative\n                    abnormality of the choroidea, which is often associated with subretinal fluid\n                    accumulation. The disease group does not currently have a standard treatment\n                    protocol; some of the multiple treatments prove to be more effective, however,\n                    there are significant differences between the subgroups. We summarize which\n                    subgroup benefits from eplerenone tablet therapy, micropulse laser therapy,\n                    verteporfin photodynamic therapy or intravitreal anti-VEGF injection therapy.\n                    Orv Hetil. 2020; 162(20): 770\u2013781.<\/jats:p>","DOI":"10.1556\/650.2021.32062","type":"journal-article","created":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T10:05:26Z","timestamp":1630404326000},"page":"770-781","update-policy":"http:\/\/dx.doi.org\/10.1556\/policypage.crossmark.crossref.1","source":"Crossref","is-referenced-by-count":1,"title":["Pachychorioidealis k\u00f3rk\u00e9pek"],"prefix":"10.1556","volume":"162","author":[{"given":"R\u00f3bert","family":"Gergely","sequence":"first","affiliation":[{"name":"1 Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Szem\u00e9szeti Klinika, Budapest, \u00dcll\u0151i u. 26., 1085"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00f3nika","family":"Ecsedy","sequence":"additional","affiliation":[{"name":"1 Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Szem\u00e9szeti Klinika, Budapest, \u00dcll\u0151i u. 26., 1085"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ill\u00e9s","family":"Kov\u00e1cs","sequence":"additional","affiliation":[{"name":"1 Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Szem\u00e9szeti Klinika, Budapest, \u00dcll\u0151i u. 26., 1085"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e1s","family":"Papp","sequence":"additional","affiliation":[{"name":"1 Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Szem\u00e9szeti Klinika, Budapest, \u00dcll\u0151i u. 26., 1085"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikl\u00f3s","family":"Resch","sequence":"additional","affiliation":[{"name":"1 Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Szem\u00e9szeti Klinika, Budapest, \u00dcll\u0151i u. 26., 1085"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zsuzsa","family":"R\u00e9cs\u00e1n","sequence":"additional","affiliation":[{"name":"1 Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Szem\u00e9szeti Klinika, Budapest, \u00dcll\u0151i u. 26., 1085"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antal","family":"Szab\u00f3","sequence":"additional","affiliation":[{"name":"1 Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Szem\u00e9szeti Klinika, Budapest, \u00dcll\u0151i u. 26., 1085"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zolt\u00e1n Zsolt","family":"Nagy","sequence":"additional","affiliation":[{"name":"1 Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Szem\u00e9szeti Klinika, Budapest, \u00dcll\u0151i u. 26., 1085"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"425","reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"3","DOI":"10.31348\/2018\/1\/1-1-2018","article-title":"Pachychoroid disease of the macula","volume":"74","author":"1 Stepanov","year":"2018","unstructured":"1 Stepanov A, Studni\u010dka J, St\u0159edov\u00e1 M, et al. Pachychoroid disease of the macula. Cesk Slov Oftalmol. 2018; 74: 3-8.","journal-title":"Cesk Slov Oftalmol"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41433-018-0158-4","article-title":"Pachychoroid disease","volume":"33","author":"2 Cheung","year":"2019","unstructured":"2 Cheung CM, Lee WK, Koizumi H, et al. Pachychoroid disease. Eye 2019; 33: 14-33.","journal-title":"Eye"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3928\/23258160-20200326-01","article-title":"Pachychoroid disease","volume":"51","author":"Freund KB","year":"2020","unstructured":"3 Freund KB, Fine HF. Pachychoroid disease. Ophthalmic Surg Lasers Imaging Retina 2020; 51: 206-209.","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"ref3","unstructured":"4 R\u00e9cs\u00e1n Zs. Importance of choroidal thickness in eye diseases. [A chorioidea-vastags\u00e1g jelent\u0151s\u00e9ge szemfen\u00e9ki k\u00f3rk\u00e9pekben.] Szem\u00e9szet 2019; 156: 48-58. [Hungarian]"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ophtha.2007.02.032","article-title":"The incidence of central serous chorioretinopathy in Olmsted county, Minnesota, 1980-2002","volume":"115","author":"5 Kitzmann","year":"2008","unstructured":"5 Kitzmann AS, Pulido JS, Diehl NN, et al. The incidence of central serous chorioretinopathy in Olmsted county, Minnesota, 1980-2002. Ophthalmology 2008; 115: 169-173.","journal-title":"Ophthalmology"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/S0161-6420(01)00951-4","article-title":"Clinical characteristics of central serous chorioretinopathy in women","volume":"109","author":"6 Perkins","year":"2002","unstructured":"6 Perkins SL, Kim JE, Pollack JS, et al. Clinical characteristics of central serous chorioretinopathy in women. Ophthalmology 2002; 109: 262-266.","journal-title":"Ophthalmology"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.preteyeres.2015.05.003","article-title":"Central serous chorioretinopathy: recent findings and new physiopathology hypothesis","volume":"48","author":"7 Daruich","year":"2015","unstructured":"7 Daruich A, Matet A, Dirani A, et al. Central serous chorioretinopathy: recent findings and new physiopathology hypothesis. Prog Retin Eye Res. 2015; 48: 82-118.","journal-title":"Prog Retin Eye Res"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1016\/S0161-6420(02)01117-X","article-title":"Corticosteroids and central serous chorioretinopathy","volume":"109","author":"8 Carvalho-Recchia","year":"2002","unstructured":"8 Carvalho-Recchia CA, Yannuzzi LA, Negr\u00e3o S, et al. Corticosteroids and central serous chorioretinopathy. Ophthalmology 2002; 109: 1834-1837.","journal-title":"Ophthalmology"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1097\/IAE.0000000000002117","article-title":"Association of obstructive sleep apnea with central serous chorioretinopathy and choroidal thickness: a systematic review and meta-analysis","volume":"38","author":"CY","year":"2018","unstructured":"9 Wu CY, Riangwiwat T, Rattanawong P, et al. Association of obstructive sleep apnea with central serous chorioretinopathy and choroidal thickness: a systematic review and meta-analysis. Retina 2018; 38: 1642-1651.","journal-title":"Retina"},{"key":"ref9","unstructured":"10 Ecsedy M, Gergely R. Central serous chorioretinopathy. In: R\u00e9cs\u00e1n Zs, Nagy ZZs. (eds.) Optical coherence tomography in ophthalmology. [Chorioretinopathia centralis serosa OCT lek\u00e9pez\u00e9se. In: R\u00e9cs\u00e1n Zs, Nagy ZZs. (szerk.) Optikai koherencia tomogr\u00e1fia a szem\u00e9szetben.] Semmelweis Kiad\u00f3, Budapest, 2018; pp. 132-137. [Hungarian]"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1097\/IAE.0b013e31820f4b39","article-title":"Subfoveal choroidal thickness in fellow eyes of patients with central serous chorioretinopathy","volume":"31","author":"11 Maruko","year":"2011","unstructured":"11 Maruko I, Iida T, Sugano Y, et al. Subfoveal choroidal thickness in fellow eyes of patients with central serous chorioretinopathy. Retina 2011; 31: 1603-1608.","journal-title":"Retina"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1016\/j.ophtha.2012.02.021","article-title":"Assessment of macular choroidal thickness by optical coherence tomography and angiographic changes in central serous chorioretinopathy","volume":"119","author":"12 Jirarattanasopa","year":"2012","unstructured":"12 Jirarattanasopa P, Ooto S, Tsujikawa A, et al. Assessment of macular choroidal thickness by optical coherence tomography and angiographic changes in central serous chorioretinopathy. Ophthalmology 2012; 119: 1666-1678.","journal-title":"Ophthalmology"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1097\/IAE.0b013e3182953df4","article-title":"Pachychoroid pigment epitheliopathy","volume":"33","author":"13 Warrow","year":"2013","unstructured":"13 Warrow DJ, Hoang QV, Freund KB. Pachychoroid pigment epitheliopathy. Retina 2013; 33: 1659-1672.","journal-title":"Retina"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14 Sanchez-Cano A, Orduna E, Segura F, et al. Choroidal thickness and volume in healthy young white adults and the relationships between them and axial length, ammetropy and sex. Am J Ophthalmol. 2014; 158: 574-583.e1.","DOI":"10.1016\/j.ajo.2014.05.035"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"5252","DOI":"10.1167\/iovs.14-14959","article-title":"Pachychoroid pigment epitheliopathy may masquerade as acute retinal pigment epitheliitis","volume":"55","author":"Pang CE","year":"2014","unstructured":"15 Pang CE, Freund KB. Pachychoroid pigment epitheliopathy may masquerade as acute retinal pigment epitheliitis. Invest Ophthalmol Vis Sci. 2014; 55: 5252.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.survophthal.2010.03.004","article-title":"Polypoidal choroidal vasculopathy: a review","volume":"55","author":"16 Imamura","year":"2010","unstructured":"16 Imamura Y, Engelbert M, Iida T, et al. Polypoidal choroidal vasculopathy: a review. Surv Ophthalmol. 2010; 55: 501-515.","journal-title":"Surv Ophthalmol"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17 Balaratnasingam C, Lee WK, Koizumi H, et al. Polypoidal choroidal vasculopathy: a distinct disease or manifestation of many? Retina 2016; 36: 1-8.","DOI":"10.1097\/IAE.0000000000000774"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1097\/01.iae.0000249386.63482.05","article-title":"Tomographic features of branching vascular networks in polypoidal choroidal vasculopathy","volume":"27","author":"18 Sato","year":"2007","unstructured":"18 Sato T, Kishi S, Watanabe G, et al. Tomographic features of branching vascular networks in polypoidal choroidal vasculopathy. Retina 2007; 27: 589-594.","journal-title":"Retina"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"4729","DOI":"10.1167\/iovs.08-2134","article-title":"Clinicopathologic findings in polypoidal choroidal vasculopathy","volume":"49","author":"19 Nakashizuka","year":"2008","unstructured":"19 Nakashizuka H, Mitsumata M, Okisaka S, et al. Clinicopathologic findings in polypoidal choroidal vasculopathy. Invest Ophthalmol Vis Sci. 2008; 49: 4729-4737.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/S0002-9394(14)70531-8","article-title":"Choroidal capillary and venous congestion in central serous chorioretinopathy","volume":"121","author":"Pr\u00fcnte C","year":"1996","unstructured":"20 Pr\u00fcnte C, Flammer J. Choroidal capillary and venous congestion in central serous chorioretinopathy. Am J Ophthalmol. 1996; 121: 26-34.","journal-title":"Am J Ophthalmol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1097\/IAE.0000000000001907","article-title":"Peripapillary pachychoroid syndrome","volume":"38","author":"21 Phasukkijwatana","year":"2018","unstructured":"21 Phasukkijwatana N, Freund KB, Dolz-Marco R, et al. Peripapillary pachychoroid syndrome. Retina 2018; 38: 1652-1667.","journal-title":"Retina"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22 Pautler SE, Browning DJ. Isolated posterior uveal effusion: expanding the spectrum of the uveal effusion syndrome. Clin Ophthalmol. 2015; 9: 43-49.","DOI":"10.2147\/OPTH.S75448"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1001\/archophthalmol.2011.148","article-title":"The expanded spectrum of focal choroidal excavation","volume":"129","author":"23 Margolis","year":"2011","unstructured":"23 Margolis R, Mukkamala SK, Jampol LM, et al. The expanded spectrum of focal choroidal excavation. Arch Ophthalmol. 2011; 129: 1320-1325.","journal-title":"Arch Ophthalmol"},{"key":"ref23","unstructured":"24 Ecsedy M, Gergely R , Kov\u00e1cs I, et al. Central serous chorioretinopathy (CSCR). New diagnostic and therapeutic possibilities. [Centr\u00e1lis serosus chorioretinopathia (CSCR). \u00daj diagnosztikus \u00e9s ter\u00e1pi\u00e1s lehet\u0151s\u00e9gek.] Szem\u00e9szet 2018; 155: 11-17. [Hungarian]"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1097\/IAE.0000000000001303","article-title":"Mineralocorticoid receptor antagonist treatment in bilateral chronic central serous chorioretinopathy: a comparative study of exudative and nonexudative fellow eyes","volume":"37","author":"25 Gergely","year":"2017","unstructured":"25 Gergely R, Kov\u00e1cs I, Schneider M, et al. Mineralocorticoid receptor antagonist treatment in bilateral chronic central serous chorioretinopathy: a comparative study of exudative and nonexudative fellow eyes. Retina 2017; 37: 1084-1091.","journal-title":"Retina"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1097\/IAE.0b013e318297a07a","article-title":"Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study","volume":"33","author":"26 Bousquet","year":"2013","unstructured":"26 Bousquet E, Beydoun T, Zhao M, et al. Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study. Retina 2013; 33: 2096-2102.","journal-title":"Retina"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"3405","DOI":"10.1096\/fj.09-154344","article-title":"The neuroretina is a novel mineralocorticoid target: aldosterone up-regulates ion and water channels in M\u00fcller glial cells","volume":"24","author":"27 Zhao","year":"2010","unstructured":"27 Zhao M, Valamanesh F, Celerier I, et al. The neuroretina is a novel mineralocorticoid target: aldosterone up-regulates ion and water channels in M\u00fcller glial cells. FASEB J. 2010; 24: 3405-3415.","journal-title":"FASEB J"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1172\/JCI61427","article-title":"Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy","volume":"122","author":"28 Zhao","year":"2012","unstructured":"28 Zhao M, C\u00e9l\u00e9rier I, Bousquet E, et al. Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J Clin Invest. 2012; 122: 2672-2679.","journal-title":"J Clin Invest"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1097\/IAE.0000000000000748","article-title":"Central serous chorioretinopathy treated with mineralocorticoid antagonists: a one-year pilot study","volume":"36","author":"29 Ghadiali","year":"2016","unstructured":"29 Ghadiali Q, Jung JJ, Yu S, et al. Central serous chorioretinopathy treated with mineralocorticoid antagonists: a one-year pilot study. Retina 2016; 36: 611-618.","journal-title":"Retina"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"16621","DOI":"10.1038\/s41598-020-73959-4","article-title":"Predictive factors of selective mineralocorticoid receptor antagonist treatment in chronic central serous chorioretinopathy","volume":"10","author":"30 Gergely","year":"2020","unstructured":"30 Gergely R, Kov\u00e1cs I, R\u00e9cs\u00e1n Zs, et al. Predictive factors of selective mineralocorticoid receptor antagonist treatment in chronic central serous chorioretinopathy. Sci Rep. 2020; 10: 16621.","journal-title":"Sci Rep"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1007\/s00417-019-04426-8","article-title":"Comparing effects of photodynamic therapy in central serous chorioretinopathy: full-dose versus half-dose versus half-dose-half-fluence","volume":"257","author":"31 Park","year":"2019","unstructured":"31 Park W, Kim M, Kim RY, et al. Comparing effects of photodynamic therapy in central serous chorioretinopathy: full-dose versus half-dose versus half-dose-half-fluence. Graefes Arch Clin Exp Ophthalmol. 2019; 257: 2155-2161.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"32 Ma J, Meng N, Xu X, et al. System review and meta-analysis on photodynamic therapy in central serous chorioretinopathy. Acta Ophthalmol. 2014; 92: e594-e601.","DOI":"10.1111\/aos.12482"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/s41433-018-0029-z","article-title":"Comparison of photodynamic therapy and navigated microsecond laser for chronic central serous chorioretinopathy","volume":"32","author":"33 Ntomoka","year":"2018","unstructured":"33 Ntomoka CG, Rajesh B, Muriithi GM, et al. Comparison of photodynamic therapy and navigated microsecond laser for chronic central serous chorioretinopathy. Eye 2018; 32: 1079-1086.","journal-title":"Eye"},{"key":"ref33","unstructured":"34 Gergely R, Ecsedy M, Nagy ZZs. Navilas micropulse laser treatment of chronic central serous chorioretinopathy (CSCR). [Kr\u00f3nikus centr\u00e1lis serosus chorioretinopathia (CSCR) Navilas\u00ae mikropulzus l\u00e9zerkezel\u00e9se.] A Magyar Szemorvost\u00e1rsas\u00e1g Retina Szekci\u00f3j\u00e1nak Kongresszusa, Gy\u0151r, 2019. [Hungarian]"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"35 van Rijssen TJ, van Dijk EH, Scholz P, et al. Focal and diffuse chronic central serous chorioretinopathy treated with half-dose photodynamic therapy or subthreshold micropulse laser: PLACE Trial Report No. 3. Am J Ophthalmol. 2019; 205: 1-10.","DOI":"10.1016\/j.ajo.2019.03.025"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1136\/bjophthalmol-2017-311291","article-title":"Yellow (577 nm) micropulse laser versus half-dose verteporfin photodynamic therapy in eyes with chronic central serous chorioretinopathy: results of the Pan-American Collaborative Retina Study (PACORES) Group","volume":"102","author":"36 Roca","year":"2018","unstructured":"36 Roca JA, Wu L, Fromow-Guerra J, et al. Yellow (577 nm) micropulse laser versus half-dose verteporfin photodynamic therapy in eyes with chronic central serous chorioretinopathy: results of the Pan-American Collaborative Retina Study (PACORES) Group. Br J Ophthalmol. 2018; 102: 1696-1700.","journal-title":"Br J Ophthalmol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s00417-010-1581-9","article-title":"The efficacy of intravitreal bevacizumab for idiopathic central serous chorioretinopathy","volume":"249","author":"Lim JW","year":"2011","unstructured":"37 Lim JW, Kim MU. The efficacy of intravitreal bevacizumab for idiopathic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2011; 249: 969-974.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1097\/IAE.0b013e31820a6a17","article-title":"Concentration of cytokines in the aqueous humor of patients with central serous chorioretinopathy","volume":"31","author":"Shin MC","year":"2011","unstructured":"38 Shin MC, Lim JW. Concentration of cytokines in the aqueous humor of patients with central serous chorioretinopathy. Retina 2011; 31: 1937-1943.","journal-title":"Retina"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"8337","DOI":"10.1038\/s41598-020-65346-w","article-title":"Association between pachychoroid and long-term treatment outcomes of photodynamic therapy with intravitreal ranibizumab for polypoidal choroidal vasculopathy","volume":"10","author":"39 Azuma","year":"2020","unstructured":"39 Azuma K, Okubo A, Nomura Y, et al. Association between pachychoroid and long-term treatment outcomes of photodynamic therapy with intravitreal ranibizumab for polypoidal choroidal vasculopathy. Sci Rep. 2020; 10: 8337.","journal-title":"Sci Rep"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1007\/s00417-020-04661-4","article-title":"One-year outcome of combination therapy with intravitreal anti-vascular endothelial growth factor and photodynamic therapy in patients with pachychoroid neovasculopathy","volume":"258","author":"40 Kitajima","year":"2020","unstructured":"40 Kitajima Y, Maruyama-Inoue M, Ito A, et al. One-year outcome of combination therapy with intravitreal anti-vascular endothelial growth factor and photodynamic therapy in patients with pachychoroid neovasculopathy. Graefes Arch Clin Exp Ophthalmol. 2020; 258: 1279-1285.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"10520","DOI":"10.1038\/s41598-018-28484-w","article-title":"Distinct aqueous humour cytokine profiles of patients with pachychoroid neovasculopathy and neovascular age-related macular degeneration","volume":"8","author":"41 Terao","year":"2018","unstructured":"41 Terao N, Koizumi H, Kojima K, et al. Distinct aqueous humour cytokine profiles of patients with pachychoroid neovasculopathy and neovascular age-related macular degeneration. Sci Rep. 2018; 8: 10520.","journal-title":"Sci Rep"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1097\/IAE.0b013e31824f91e8","article-title":"EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy","volume":"32","author":"42 Koh","year":"2012","unstructured":"42 Koh A, Lee WK, Chen LJ, et al. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina 2012; 32: 1453-1464.","journal-title":"Retina"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1001\/jamaophthalmol.2017.4030","article-title":"Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: a randomized clinical trial","volume":"135","author":"43 Koh","year":"2017","unstructured":"43 Koh A, Lai TY, Takahashi K, et al. Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: a randomized clinical trial. JAMA Ophthalmol. 2017; 135: 1206-1213.","journal-title":"JAMA Ophthalmol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1136\/bjophthalmol-2018-312419","article-title":"Long-term results of photodynamic therapy or ranibizumab for polypoidal choroidal vasculopathy in LAPTOP study","volume":"103","author":"44 Miyamoto","year":"2019","unstructured":"44 Miyamoto N, Mandai M, Oishi A, et al. Long-term results of photodynamic therapy or ranibizumab for polypoidal choroidal vasculopathy in LAPTOP study. Br J Ophthalmol. 2019; 103: 844-848.","journal-title":"Br J Ophthalmol"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"45 Lee WK, Iida T, Ogura Y, et al. Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET study: a randomized clinical trial. JAMA Ophthalmol. 2018; 136: 786-793. [Erratum: JAMA Ophthalmol. 2018; 136: 840.]","DOI":"10.1001\/jamaophthalmol.2018.1804"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1159\/000360308","article-title":"Comparison of the outcomes of photodynamic therapy between two angiographic subtypes of polypoidal choroidal vasculopathy","volume":"232","author":"46 Honda","year":"2014","unstructured":"46 Honda S, Miki A, Yanagisawa S, et al. Comparison of the outcomes of photodynamic therapy between two angiographic subtypes of polypoidal choroidal vasculopathy. Ophthalmologica 2014; 232: 92-96.","journal-title":"Ophthalmologica"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"47 Gemmy Cheung CM, Yeo I, Li X, et al. Argon laser with and without anti-vascular endothelial growth factor therapy for extrafoveal polypoidal choroidal vasculopathy. Am J Ophthalmol. 2013; 155: 295-304.e1.","DOI":"10.1016\/j.ajo.2012.08.002"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"296","DOI":"10.4274\/tjo.24445","article-title":"Focal choroidal excavation","volume":"46","author":"48 Cebeci","year":"2016","unstructured":"48 Cebeci Z, Bayraktar \u015e, Oray M, et al. Focal choroidal excavation. Turk J Ophthalmol. 2016; 46: 296-298.","journal-title":"Turk J Ophthalmol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3928\/23258160-20191211-08","article-title":"Focal choroidal excavation expansion following treatment of associated choroidal neovascular membrane","volume":"51","author":"49 Kov\u00e1cs","year":"2019","unstructured":"49 Kov\u00e1cs KD, Gonzalez LA, Weiss SJ, et al. Focal choroidal excavation expansion following treatment of associated choroidal neovascular membrane. Ophthalmic Surg Lasers Imaging Retina 2019; 51: 54-57.","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.oftale.2020.01.014","article-title":"Diagnosis by multimodal imaging in peripapillary pachychoroid syndrome: a case report","volume":"95","author":"50 Alonso-Mart\u00edn","year":"2020","unstructured":"50 Alonso-Mart\u00edn B, de-Lucas-Viejo B, Gimeno-Carrero M, et al. Diagnosis by multimodal imaging in peripapillary pachychoroid syndrome: a case report. Arch Soc Esp Oftalmol. 2020; 95: 248-253.","journal-title":"Arch Soc Esp Oftalmol"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/162\/20\/article-p770.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/162\/20\/article-p770.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T12:34:45Z","timestamp":1698755685000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/162\/20\/article-p770.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,16]]},"references-count":50,"journal-issue":{"issue":"20"},"URL":"https:\/\/doi.org\/10.1556\/650.2021.32062","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,16]]}}}